AstraZeneca and the Bellvitge University Hospital launched the first pilot program for the Cordio Medical HearO app, which can sense fluid accumulation related to CHF (Congestive Heart Failure) using only the patient’s speech, sampled via his mobile device.
The pilot will monitor HearO™’s success rates in achieving patient compliance and HearO™’s ability to issue notices before potential heart failure events over a six- to nine-month period.
Previous and ongoing studies in Israel and the U.S. tested and validated the technology. Those demonstrated an 82% success rate in predicting a heart decompensation event up to 22 days before the occurrence.
